General Information

Mail: University of Houston
Cullen College of Engineering
E421 Engineering Bldg 2, Houston, TX 77204-4007
Map & Driving Directions (includes parking information)
Email: info [at] egr [dot] uh [dot] edu

News

BMI Workshop Recounted in IEEE Pulse

Printer-friendly versionSend by emailPDF version

By: 

Toby Weber

A group of graduate students studying under Jose Luis Contreras-Vidal, professor of electrical and computer engineering at the University of Houston Cullen College of Engineering, have published an account of the 2013 Workshop of Clinical Brain-Neural Machine Interface Systems.

The workshop was held in Houston last February and brought together the world’s leading figures in the area of brain-computer/machine interfaces (BCI/BMI). These technologies could someday revolutionize care and quality of life for those dealing with paralysis, amputation, brain injury and other conditions by allowing them to control everything from robotic exoskeletons to high-tech prosthetics using only their thoughts

The gathering, hosted by University of Houston and The Methodist Hospital Research Institute, was designed to make that day come as quickly as possible. BCI/BMI systems are still in the development stage. To bring them from the lab to the clinic, the BCI/BMI community must create a “roadmap” that defines the roles of everyone involved in these efforts, including researchers, regulators, funding agencies and investors. Several working groups that grew out of the conference are now developing sections of the roadmap.

The account of the workshop, co-written by representatives from the National Institute of Health, appears in the most recent issue of IEEE Pulse.

Faculty: 

Department: 

Related News Stories

Researcher Publishes Paper on Engineered Antibody that Targets Acute Myeloid Leukemia

Almost 19,000 new cases of acute myeloid leukemia and 10,500 deaths from the blood and bone marrow cancer could strike Americans this year, according to the American Cancer Society. Chemotherapy, when used as primary treatment, is successful in about 65 percent of patients with the cancer, and remission rates vary depending on patients’ individual characteristics, according to the organization.

Upcoming Events / Seminars

Archived News